Study S001256

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07282613
Acronym: REIMAGINEYOUNG
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 80
Start: 2026-08-04
Primary completion: 2029-09-07
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:CagriSema (Cagrilintide B and Semaglutide I); DRUG:Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1307-6786; OTHER:2024-514432-24

Registered primary outcomes

Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of double-blinded treatment (week 26)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.